Business
Clinuvel (ASX:CUV) share price pinches down after Israeli breakthrough // The Motley Fool Australia
The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price closed 1.15% lower today at $21.54. The dip came after the company announced that its SCENESSE product had been added to Israel’s ‘National Health Basket’ (NHB) of reimbursable services and products.
Clinuvel Pharmaceuticals is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of genetic and vascular disorders.
The company’s main product is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP).
What’s driving the Clinuvel share price?
Earlier today, Clinuvel announced that it had achieved a positive outcome in Israel regarding its SCENESSE treatment. The product, which is…
-
General10 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News19 hours agoRainbow Beach surfer’s untold 7/7 story
-
Noosa News12 hours agoWoman left with significant arm injuries in lion attack at Darling Downs Zoo in Queensland
-
General24 hours agoDr Daniel Hunt, Michael Long and Christine Anu celebrated at 50th NAIDOC Week Awards